Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

About the Cover

December 1, 2014; Volume 55,Issue 12

Cover image

Cover image expansion

18F-mefway exhibits favorable in vivo properties for serotonin 5-HT1A receptor measurements in humans. It is an attractive PET radiotracer for neuropsychiatric disorders and drug intervention. See page 1973.

Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 55 (12)
Journal of Nuclear Medicine
Vol. 55, Issue 12
December 1, 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author

Issue highlights

  • Perceived Misinterpretation Rates in Oncologic 18F-FDG PET/CT Studies: A Survey of Referring Physicians
  • Comparison and Prognostic Validation of Multiple Methods of Quantification of Myocardial Blood Flow with 82Rb PET
  • First-in-Human Evaluation of 18F-Mefway, a PET Radioligand Specific to Serotonin-1A Receptors
  • Multimodality Imaging of Alzheimer Disease and Other Neurodegenerative Dementias
Sign up for alerts

Jump to

  • This Month in JNM
  • SNMMI Newsline
  • Focus on Molecular Imaging
  • Invited Perspectives
  • Clinical Investigations
  • Continuing Education
  • Basic Science Investigations
  • Book Reviews
  • Letters to the Editor
  • Most Cited
  • Most Read
Loading
  • First-in-Human Assessment of 11C-LSN3172176, an M1 Muscarinic Acetylcholine Receptor PET Radiotracer
  • Performance Evaluation of the uEXPLORER Total-Body PET/CT Scanner Based on NEMA NU 2-2018 with Additional Tests to Characterize PET Scanners with a Long Axial Field of View
  • Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients
  • Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
  • Is FDG maximum standardized uptake value (SUV max) of primary breast cancer can predict axillary lymph node metastasis?
More...
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire